{"id":"ethinylestradiol-sulfonate","rwe":[{"pmid":"9483810","year":"1997","title":"[Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations].","finding":"","journal":"Zentralblatt fur Gynakologie","studyType":"Clinical Study"},{"pmid":"2513213","year":"1989","title":"Pituitary response in the doubled GnRH-TRH test on the 5th day post partum or post abortum after ablactation by oral means of ethinylestradiol sulfonate.","finding":"","journal":"Experimental and clinical endocrinology","studyType":"Clinical Study"},{"pmid":"2630306","year":"1989","title":"Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer.","finding":"","journal":"Experimental and clinical endocrinology","studyType":"Clinical Study"},{"pmid":"3051628","year":"1988","title":"[Combination hormone-chemotherapy versus hormone therapy alone in the initial treatment of advanced prostate carcinoma--a prospective cooperative study].","finding":"","journal":"Der Urologe. Ausg. A","studyType":"Clinical Study"},{"pmid":"3604471","year":"1987","title":"[Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].","finding":"","journal":"Zeitschrift fur Urologie und Nephrologie","studyType":"Clinical Study"}],"tags":[{"label":"Estrogen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Contraceptive Agents","category":"pharmacology"},{"label":"Contraceptive Agents, Female","category":"pharmacology"},{"label":"Contraceptive Agents, Hormonal","category":"pharmacology"},{"label":"Contraceptives, Oral, Hormonal","category":"pharmacology"},{"label":"Estrogens","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"turisteron","offLabel":[],"synonyms":["ethinyl estradiol sulfonate","2-Propanesulfonic acid, 17-hydroxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-3-yl ester","turisteron","ethinylestradiol sulfonate"],"timeline":[],"approvals":[],"brandName":"Turisteron","ecosystem":[],"mechanism":{"moaClass":"Estrogen Receptor Agonists","modality":"Small Molecule","drugClass":"Estrogen","explanation":"Think of estrogen receptors like locks on a door. When Turisteron binds to these receptors, it's like having a key that unlocks the door, allowing estrogen to influence how cells grow and function. This can have various effects on the body, depending on the specific cells and tissues involved.","oneSentence":"Turisteron works by binding to estrogen receptors in the body, influencing gene expression and cellular activity.","technicalDetail":"Turisteron, as an estrogen, exerts its effects by binding to estrogen receptors (ERα and ERβ), which are transcription factors that regulate gene expression by interacting with specific DNA sequences. This binding event triggers a cascade of downstream effects, including the activation of estrogen-responsive genes and the modulation of cellular signaling pathways."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ethinylestradiol_sulfonate","title":"Ethinylestradiol sulfonate","extract":"Ethinylestradiol sulfonate (EES), sold under the brand names Deposiston and Turisteron among others, is an estrogen medication which has been used in birth control pills for women and in the treatment of prostate cancer in men. It has also been investigated in the treatment of breast cancer in women. The medication was combined with norethisterone acetate in birth control pills. EES is taken by mouth once per week.","wiki_history":"==History==\nEES was first synthesized in 1967 at Jenapharm. It was first introduced for use in combination with norethisterone acetate under the brand name Deposiston as a once-a-week birth control pill for women in 1978. The medication was subsequently introduced by itself under the brand name Turisteron for the treatment of prostate cancer in men in 1980.","wiki_society_and_culture":"==Society and culture==\n\n===Generic names===\nEthinylestradiol sulfonate is the generic name of the drug, but it is also commonly known by its brand names Deposiston and Turisteron. It does not appear to have an  or other such designations."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3943","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ethinylestradiol sulfonate","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Ethinylestradiol_sulfonate","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:16:02.766926","biosimilars":[],"competitors":[],"genericName":"ethinylestradiol sulfonate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"4698","NDDF":"001286","UNII":"XF48685MYR","CHEBI":"CHEBI:136600","VANDF":"4018022","INN_ID":"437","RXNORM":"4124","UMLSCUI":"C0059716","DRUGBANK_ID":"DB00977","PDB_CHEM_ID":" 3WF","PUBCHEM_CID":"68575","SNOMEDCT_US":"126097006","MESH_DESCRIPTOR_UI":"D004997","MESH_SUPPLEMENTAL_RECORD_UI":"C025723"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":14,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1997","pmid":"9483810","title":"[Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations].","journal":"Zentralblatt fur Gynakologie"},{"date":"1989 Sep","pmid":"2513213","title":"Pituitary response in the doubled GnRH-TRH test on the 5th day post partum or post abortum after ablactation by oral means of ethinylestradiol sulfonate.","journal":"Experimental and clinical endocrinology"},{"date":"1989","pmid":"2630306","title":"Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer.","journal":"Experimental and clinical endocrinology"},{"date":"1988 Sep","pmid":"3051628","title":"[Combination hormone-chemotherapy versus hormone therapy alone in the initial treatment of advanced prostate carcinoma--a prospective cooperative study].","journal":"Der Urologe. Ausg. A"},{"date":"1987 Mar","pmid":"3604471","title":"[Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].","journal":"Zeitschrift fur Urologie und Nephrologie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Turisteron (ethinylestradiol sulfonate) is a small molecule estrogen drug of unknown target and commercial status. It is classified as an estrogen, but its specific indications, half-life, bioavailability, and generic availability are unknown. As an estrogen, Turisteron is likely to work by binding to estrogen receptors in the body, influencing gene expression and cellular activity. However, without more information, its therapeutic applications and safety profile cannot be fully assessed. Further research is needed to determine the drug's efficacy and potential risks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}